[go: up one dir, main page]

AR040925A1 - Compuestos de pirazol utiles como inhibidores de proteinquinasa - Google Patents

Compuestos de pirazol utiles como inhibidores de proteinquinasa

Info

Publication number
AR040925A1
AR040925A1 ARP010105963A ARP010105963A AR040925A1 AR 040925 A1 AR040925 A1 AR 040925A1 AR P010105963 A ARP010105963 A AR P010105963A AR P010105963 A ARP010105963 A AR P010105963A AR 040925 A1 AR040925 A1 AR 040925A1
Authority
AR
Argentina
Prior art keywords
ring
so2n
con
independently selected
nitrogen
Prior art date
Application number
ARP010105963A
Other languages
English (en)
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of AR040925A1 publication Critical patent/AR040925A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)

Abstract

Un compuesto de pirazol Ăștil como inhibidor de proteinquinasa que responde a fĂłrmula (1), o un derivado o prodroga farmacĂ©uticamente aceptable del mismo, en donde: Rx y Ry son seleccionados independientemente de T-R3 Ăł L-Z-R3; R1 es T-(anillo D); el anillo D es un anillo monocĂ­clico de 5-7 miembros o un anillo bicĂ­clico de 8-10 miembros seleccionado entre arilo, heteroarilo, heterociclilo o carbociclilo, teniendo dicho anillo heteroarilo o heterociclilo 1-4 heteroĂĄtomos en el anillo seleccionados entre nitrĂłgeno, oxĂ­geno o azufre, en donde el anillo D estĂĄ sustituido en cualquier ĂĄtomo de carbono sustituible del anillo por oxo, T-R5, o V-Z-R5, y en cualquier ĂĄtomo de nitrĂłgeno del anillo por -R4; T es una ligadura de valencia o una cadena de alquilideno C1-4; Z es una cadena alquilideno C1-4; L es -O-, -S-, -SO-, -SO2-, -N(R6)SO2-, -SO2N(R6)-, -N(R6)-, -CO-, -CO2-, -N(R6)CO-, -N(R6)C(O)O-, -N(R6)CON(R6)-, -N(R6)SO2N(R6)-, -N(R6)N(R6)-, -C(O)N(R6)-, -OC(O)N(R6)-, -C(R6)2O-, -C(R6)2S-, -C(R6)2SO-, -C(R6)2SO2-, -C(R6)2SO2N(R6)-, -C(R6)2N(R6)-, -C(R6)2N(R6)C(O)-, -C(R6)2N(R6)C(O)O-, -CR6)=NN(R6)-, -C(R6)=N-O-, -C(R6)2N(R6)N(R6)-, -C(R6)2N(R6)SO2N(R6)-, Ăł -C(R6)2N(R6)CON(R6)-; R2 y R2' son seleccionados independientemente entre -R, -T-W-R6, Ăł R2 y R2' son tomados conjuntamente con los ĂĄtomos a los cuales estĂĄn unidos para formar un anillo fusionado de 5-8 miembros, no saturado o parcialmente no saturado, que tiene 0-3 heteroĂĄtomos en el anillo, seleccionados entre nitrĂłgeno, oxĂ­geno o azufre, en donde cualquier carbono sustituible de dicho anillo fusionado formado por R2 y R2' estĂĄ sustituido por halo, oxo, -CN, -NO2, -R7 Ăł -V-R6, y cualquier nitrĂłgeno sustituible de dicho anillo formado por R2 y R2' estĂĄ sustituido por R4; R3 es seleccionado entre -R, -halo, -OR, -C(=O)R, -CO2R, -COCOR, -COCH2COR, -NO2, -CN, -S(O)R, -S(O)2R, -SR, -N(R4)2, -CON(R7)2, -SO2N(R7)2, -OC(=O)R, -N(R7)COR, -N(R7)CO2(alifĂĄtico C1-6), -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N(R7)CON(R7)2, -N(R7)SO2N(R7)2, -N(R4)SO2R, Ăł -OC(=O)N(R7)2; cada R es seleccionado independientemente entre hidrĂłgeno o un grupo opcionalmente sustituido seleccionado entre alifĂĄtico C1-6, arilo C6-10, un anillo heteroarilo, que tiene 5-10 ĂĄtomos de anillo, o un anillo heterociclilo que tiene 5-10 ĂĄtomos de anillo; cada R4 es seleccionado independientemente entre -R7, -COR7, -CO2(alifĂĄtico C1-6) opcionalmente sustituido), -CON(R7)2, Ăł -SO2R7; cada R5 es seleccionado independientemente entre -R, halo, -OR, -C(=O)R, -CO2R, -COCOR, -NO2, -CN, -S(O)R, -S(O)2R, -SR, -N(R4)2, -CON(R4)2, -SO2N(R4)2, -OC(=O)R, -N(R4)COR, -N(R4)CO2(alifĂĄtico C1-6 opcionalmente sustituido), -N(R4)N(R4)2, -C=NN(R4)2, -C=N-OR, -N(R4)CON(R4)2, -N(R4)SO2N(R4)2, -N(R4)SO2R, Ăł -OC(=O)N(R4)2; V es -O-, -S-, -SO-, -SO2-, -N(R6)SO2-, -SO2N(R6)-, -N(R6)-, -CO-, -CO2-, -N(R6)CO-, -N(R6)C(O)O-, -N(R6)CON(R6)-, -N(R6)SO2N(R6)-, -N(R6)N(R6)-, -C(O)N(R6)-, -OC(O)N(R6)-, -C(R6)2O-, -C(R6)2S-, -C(R6)2SO-, -C(R6)2SO2-, -C(R6)2SO2N(R6)-, -C(R6)2N(R6)-, -C(R6)2N(R6)C(O)-, -C(R6)2N(R6)C(O)O-, -C(R6)=NN(R6)-, -C(R6)=N-O-, -C(R6)2N(R6)N(R6)-, -C(R6)2N(R6)SO2N(R6)-, Ăł -C(R6)2N(R6)CON(R6)-; W es -C(R6)2-O, -C(R6)2S-, -C(R6)2SO-, -C(R6)2SO2-, -C(R6)2SO2N(R6)-, -C(R6)2N(R6)-, -CO-, -CO2-, -C(R6)OC(O)-, -C(R6)OC(O)N(R6)-, -C(R6)2N(R6)CO-, -C(R6)2N(R6)C(O)O-, -C(R6)=NN(R6)-, -C(R6)=N-O-, -C(R6)2N(R6)N(R6)-, -C(R6)2N(R6)SO2N(R6)-, -C(R6)2N(R6)CON(R6)-, Ăł -CON(R6)-; cada R6 es seleccionado independientemente entre hidrĂłgeno o un grupo alifĂĄtico C1-4 opcionalmente sustituido, o dos grupos R6 sobre el mismo ĂĄtomo de nitrĂłgeno son tomados conjuntamente con el ĂĄtomo de nitrĂłgeno para formar un anillo heterociclilo o heteroarilo de 5-6 miembros; y cada R7 es seleccionado independientemente entre hidrĂłgeno o un grupo alifĂĄtico C1-6 opcionalmente sustituido, o dos R7 sobre el mismo nitrĂłgeno son tomados conjuntamente con el nitrĂłgeno para formar un anillo heterociclilo o heteroarilo de 5-8 miembros. Los compuestos son Ăștiles como inhibidores de proteinquinasas especialmente como inhibidores de Aurora-2 y GSK-3, para tratar enfermedades tales como cĂĄncer, diabetes y enfermedad de Alzheimer.
ARP010105963A 2000-12-21 2001-12-20 Compuestos de pirazol utiles como inhibidores de proteinquinasa AR040925A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25788700P 2000-12-21 2000-12-21
US28694901P 2001-04-27 2001-04-27

Publications (1)

Publication Number Publication Date
AR040925A1 true AR040925A1 (es) 2005-04-27

Family

ID=26946273

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP010105962A AR042169A1 (es) 2000-12-21 2001-12-20 Compuestos de pirazol utiles como inhibidores de proteinquinasa
ARP010105960A AR042397A1 (es) 2000-12-21 2001-12-20 Compuestos de pirazol utiles como inhibidores de proteinquinasa
ARP010105963A AR040925A1 (es) 2000-12-21 2001-12-20 Compuestos de pirazol utiles como inhibidores de proteinquinasa
ARP010105961A AR042398A1 (es) 2000-12-21 2001-12-20 Compuestos de pirazol utiles como inhibidores de proteinquinasa

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP010105962A AR042169A1 (es) 2000-12-21 2001-12-20 Compuestos de pirazol utiles como inhibidores de proteinquinasa
ARP010105960A AR042397A1 (es) 2000-12-21 2001-12-20 Compuestos de pirazol utiles como inhibidores de proteinquinasa

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP010105961A AR042398A1 (es) 2000-12-21 2001-12-20 Compuestos de pirazol utiles como inhibidores de proteinquinasa

Country Status (27)

Country Link
US (16) US6653300B2 (es)
EP (10) EP1353916B1 (es)
JP (19) JP4160392B2 (es)
KR (8) KR100875091B1 (es)
CN (6) CN1486310A (es)
AP (2) AP1588A (es)
AR (4) AR042169A1 (es)
AT (9) ATE354573T1 (es)
AU (7) AU2001297619B2 (es)
BR (2) BR0116493A (es)
CA (8) CA2432223C (es)
CY (1) CY1106297T1 (es)
DE (8) DE60119776T2 (es)
DK (3) DK1353916T3 (es)
ES (7) ES2375491T3 (es)
HU (5) HUP0400638A2 (es)
IL (8) IL156389A0 (es)
MX (8) MXPA03005607A (es)
MY (1) MY140377A (es)
NO (5) NO328537B1 (es)
NZ (8) NZ526471A (es)
PL (2) PL210414B1 (es)
PT (3) PT1345922E (es)
RU (1) RU2355688C2 (es)
SI (2) SI1355905T1 (es)
TW (2) TWI290551B (es)
WO (8) WO2002059111A2 (es)

Families Citing this family (379)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982260B1 (en) 1999-11-22 2006-01-03 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ATE346064T1 (de) * 2000-09-15 2006-12-15 Vertex Pharma Pyrazolverbindungen als protein-kinasehemmer
US20020111353A1 (en) * 2000-12-05 2002-08-15 Mark Ledeboer Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
ATE354573T1 (de) * 2000-12-21 2007-03-15 Vertex Pharma ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß
PE20021011A1 (es) * 2001-03-23 2003-02-01 Bayer Corp Derivados quinazolinicos como inhibidores de la rho-quinasa
DE60227492D1 (de) 2001-04-10 2008-08-21 Merck & Co Inc Hemmstoffe der akt aktivitÀt
US7105667B2 (en) * 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
US7138404B2 (en) * 2001-05-23 2006-11-21 Hoffmann-La Roche Inc. 4-aminopyrimidine derivatives
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
WO2003026665A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
ATE495741T1 (de) 2001-09-26 2011-02-15 Pfizer Italia Srl Aminoindazolderivate mit kinaseinhibierender wirkung, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
JP4237066B2 (ja) * 2002-01-10 2009-03-11 ă‚šăƒ•ïŒŽăƒ›ăƒ•ăƒžăƒłâˆ’ăƒ© ăƒ­ă‚·ăƒ„ ă‚ąăƒŒă‚ČăƒŒ éȘšćœąæˆă‚’ćą—ćŠ ă•ă›ă‚‹ăŸă‚ăźè–Źç‰©ăźèŁœé€ ă«ăŠă‘ă‚‹ïŒ§ïŒłïŒ«âˆ’ïŒ“ÎČé˜»ćźłć‰€ăźäœżç”š
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
SG159380A1 (en) * 2002-02-06 2010-03-30 Vertex Pharma Heteroaryl compounds useful as inhibitors of gsk-3
EP1485381B8 (en) 2002-03-15 2010-05-12 Vertex Pharmaceuticals Incorporated Azolylaminoazine as inhibitors of protein kinases
EP1485380B1 (en) * 2002-03-15 2010-05-19 Vertex Pharmaceuticals Incorporated Azolylaminoazines as inhibitors of protein kinases
US7091343B2 (en) 2002-03-15 2006-08-15 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
WO2003086394A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
EP1552842A1 (en) 2002-06-07 2005-07-13 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
WO2004009602A1 (en) * 2002-07-23 2004-01-29 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
ATE451104T1 (de) 2002-07-29 2009-12-15 Rigel Pharmaceuticals Inc Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
CN1319968C (zh) * 2002-08-02 2007-06-06 æČƒæł°ć…‹æ–ŻèŻç‰©è‚Ąä»œæœ‰é™ć…Źćž 甚䜜gsk3çš„æŠ‘ćˆ¶ć‰‚çš„ćĄć”‘ç»„ćˆç‰©
SI1532145T1 (sl) * 2002-08-02 2007-02-28 Vertex Pharma Pirazolni sestavki, koristni kot inhibitorji GSK-3
FR2844267B1 (fr) * 2002-09-05 2008-02-15 Aventis Pharma Sa Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
CN1678589A (zh) * 2002-09-05 2005-10-05 漉侇ç‰čćŒ»èŻè‚Ąä»œæœ‰é™ć…Źćž 䜜äžșèŻç‰©çš„æ–°æ°šćŸșćČć”‘èĄç”Ÿç‰©äžŽć«æœ‰ćźƒä»Źçš„èŻç‰©ç»„ćˆç‰©
AU2003255482A1 (en) * 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
EP1558585B1 (en) * 2002-10-04 2013-09-25 Prana Biotechnology Limited Neurologically-active compounds
KR100490893B1 (ko) * 2002-10-11 2005-05-23 (ìŁŒ) ëč„엔씚바읎였팜 2-ë©”í†Ąì‹œ-1,3,5-íŠžëŠŹì•„ì§„ 유도ìČŽ, ê·ž ì œìĄ°ë°©ëȕ 및 읎넌 포핹하는 í•­ë°”ìŽëŸŹìŠ€ìš© 앜학적 ìĄ°ì„±ëŹŒ
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
FR2847253B1 (fr) * 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
US7309701B2 (en) 2002-11-19 2007-12-18 Sanofi-Aventis Deutschland Gmbh Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
US7462613B2 (en) 2002-11-19 2008-12-09 Sanofi-Aventis Deutschland Gmbh Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
US7423148B2 (en) 2002-11-21 2008-09-09 Chiron Corporation Small molecule PI 3-kinase inhibitors and methods of their use
WO2004072029A2 (en) * 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
WO2004087679A1 (en) * 2003-04-01 2004-10-14 Aponetics Ag 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
US20060135541A1 (en) * 2003-06-02 2006-06-22 Astrazeneca Ab (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
WO2004112719A2 (en) 2003-06-19 2004-12-29 Smithkline Beecham Corporation Chemical compounds
CN1984660B (zh) 2003-07-03 2010-12-15 çŸŽç‘žćŸ·ç”Ÿç‰©ć·„çš‹ć…Źćž 䜜äžșć€©ć†Źæ°šé…žç‰čćŒ‚æ€§ćŠèƒ±æ°šé…žè›‹ç™œé…¶æŽ»ćŒ–ć‰‚ć’Œç»†èƒžçš‹ćșæ­»äșĄèŻ±ćŻŒć‰‚çš„4-èŠłćŸșæ°šćŸș-ć–č攑敉
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
GB0315966D0 (en) * 2003-07-08 2003-08-13 Cyclacel Ltd Compounds
BRPI0412259B1 (pt) 2003-07-22 2019-08-20 Astex Therapeutics Limited Compostos de 1H-pirazol 3,4-dissubstituĂ­dos como moduladores de quinases dependentes de ciclina (CDK), seus usos, processo para a preparação dos mesmos e composição farmacĂȘutica
JP2007500179A (ja) * 2003-07-30 2007-01-11 ă‚”ă‚€ă‚Żăƒ©ă‚»ăƒ«ăƒ»ăƒȘミテッド ă‚­ăƒŠăƒŒă‚Œé˜»ćźłć‰€ăšă—ăŠăźïŒ’âˆ’ă‚ąăƒŸăƒŽăƒ•ă‚§ăƒ‹ăƒ«âˆ’ïŒ”âˆ’ăƒ•ă‚§ăƒ‹ăƒ«ăƒ”ăƒȘミゾン
ES2421139T3 (es) 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevenciĂłn de enfermedades autoinmunitarias
US20060024690A1 (en) * 2003-09-19 2006-02-02 Kao H P Normalization of data using controls
US7417726B2 (en) * 2003-09-19 2008-08-26 Applied Biosystems Inc. Normalization of data using controls
US20050221357A1 (en) * 2003-09-19 2005-10-06 Mark Shannon Normalization of gene expression data
US20050124562A1 (en) * 2003-09-23 2005-06-09 Joseph Guiles Bis-quinazoline compounds for the treatment of bacterial infections
KR20060123164A (ko) 2003-10-17 2006-12-01 아슀튞띌제넀ìčŽ ì•„ëČ  암 ìč˜ëŁŒì— ì‚Źìš©í•˜êž° 위한 4-(í”ŒëŒìĄž-3-ìŒì•„ëŻžë…ž)í”ŒëŠŹëŻžë”˜ìœ ë„ìČŽ
WO2005056547A2 (en) * 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
RU2006124559A (ru) * 2003-12-09 2008-01-20 ВДртДĐșс Đ€Đ°Ń€ĐŒĐ°ŃŃŒŃŽŃ‚ĐžĐșалз Đ˜ĐœĐșĐŸŃ€ĐżĐŸŃ€Đ”ĐčтДЎ (Us) ĐŸŃ€ĐŸĐžĐ·ĐČĐŸĐŽĐœŃ‹Đ” ĐœĐ°Ń„Ń‚ĐžŃ€ĐžĐŽĐžĐœĐ° Đž ĐżŃ€ĐžĐŒĐ”ĐœĐ”ĐœĐžĐ” уĐșĐ°Đ·Đ°ĐœĐœŃ‹Ń… ĐżŃ€ĐŸĐžĐ·ĐČĐŸĐŽĐœŃ‹Ń…Ń‹Ń… ĐČ ĐșачДстĐČĐ” ĐŒĐŸĐŽŃƒĐ»ŃŃ‚ĐŸŃ€ĐŸĐČ ĐŒŃƒŃĐșĐ°Ń€ĐžĐœĐŸĐČых Ń€Đ”Ń†Đ”ĐżŃ‚ĐŸŃ€ĐŸĐČ
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
US7534798B2 (en) 2004-02-11 2009-05-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005083105A2 (en) * 2004-02-26 2005-09-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glycogen synthase kinase 3 beta (gsk3b)
CA2560111A1 (en) * 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
JP4790703B2 (ja) * 2004-04-07 2011-10-12 æ­Šç”°è–Źć“ć·„æ„­æ ȘćŒäŒšç€Ÿ ç’°ćŒćŒ–ćˆç‰©
JP2007533717A (ja) * 2004-04-21 2007-11-22 ケă‚čăƒˆăƒ©ă‚Œăƒă‚« ă‚ąă‚Żăƒăƒœăƒ©ă‚° ćŒ–ćˆç‰©
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
US7880000B2 (en) * 2004-05-07 2011-02-01 Amgen Inc. Protein kinase modulators and method of use
US7793137B2 (en) 2004-10-07 2010-09-07 Cisco Technology, Inc. Redundant power and data in a wired data telecommunincations network
SI1771450T1 (sl) * 2004-05-14 2008-06-30 Millennium Pharm Inc Spojine in postopki za inhibiranje mitotične progresije z inhibicijo kinaze Aurora
JP4993604B2 (ja) * 2004-05-14 2012-08-08 ăƒăƒŒăƒ†ăƒƒă‚Żă‚č ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ピロăƒȘăƒ«ăƒ”ăƒȘăƒŸă‚žăƒłïœ…ïœ’ïœ‹ăƒ—ăƒ­ăƒ†ă‚€ăƒłă‚­ăƒŠăƒŒă‚Œă‚€ăƒłăƒ’ăƒ“ă‚żăƒŒăźăƒ—ăƒ­ăƒ‰ăƒ©ăƒƒă‚°
AU2012200416B2 (en) * 2004-05-14 2014-07-31 Millennium Pharmaceuticals, Inc. "Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase"
US20050255485A1 (en) * 2004-05-14 2005-11-17 Livak Kenneth J Detection of gene duplications
EP2261226B1 (en) 2004-05-14 2015-04-01 Millennium Pharmaceuticals, Inc. Methods for preparing aurora kinase inhibitors
JP2007538102A (ja) * 2004-05-20 2007-12-27 ăƒă‚€ă‚šăƒ«ăƒ»ăƒ•ă‚ąăƒŒăƒžă‚·ăƒŠăƒŒăƒă‚«ăƒ«ă‚șăƒ»ă‚łăƒŒăƒăƒŹăƒŒă‚·ăƒšăƒł çł–ć°żç—…ăźć‡Šçœźă«æœ‰ç”šăȘïŒ•âˆ’ă‚ąăƒ‹ăƒȘăƒŽâˆ’ïŒ”âˆ’ăƒ˜ăƒ†ăƒ­ă‚ąăƒȘăƒŒăƒ«ăƒ”ăƒ©ă‚ŸăƒŒăƒ«èȘ˜ć°Žäœ“
KR20070034519A (ko) * 2004-05-27 2007-03-28 읎 아읎 듀폰 디 ë„€ëȘšì•„ 앀드 ìș„파니 ꎑ감성 쀑합ìČŽ ëłŽí˜žìž”ìš© 현상제
JP4990766B2 (ja) * 2004-07-01 2012-08-01 ă‚·ăƒłă‚ż ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ă‚łăƒŒăƒăƒŹăƒŒă‚·ăƒ§ăƒł äșŒçœźæ›ćž‹ăƒ˜ăƒ†ăƒ­ă‚ąăƒȘăƒŒăƒ«ćŒ–ćˆç‰©
CN101031551A (zh) * 2004-07-06 2007-09-05 ćź‰ć‰æ°žç”Ÿç‰©ćˆ¶èŻć…Źćž 针ćŻč癌症æČ»ç–—çš„è‚ç»†èƒžç”Ÿé•żć› ć­/cmet掻性的ć–čć”‘ć•‰è°ƒèŠ‚ć‰‚
EP1778669A2 (en) * 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
TW200624431A (en) * 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
EP1797047B1 (en) * 2004-09-30 2012-01-25 Tibotec Pharmaceuticals Hiv inhibiting 5-substituted pyrimidines
MX2007003797A (es) * 2004-09-30 2007-04-23 Tibotec Pharm Ltd 5-heterociclil pirimidinas inhibidoras del virus de inmunodeficiencia humana.
CA2573976C (en) * 2004-09-30 2014-04-29 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines
ATE479687T1 (de) * 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
PE20060600A1 (es) * 2004-10-29 2006-07-14 Banyu Pharma Co Ltd Derivados de aminopiridina como inhibidores selectivos de la aurora a quinasa
US7491720B2 (en) 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
WO2006050476A2 (en) 2004-11-03 2006-05-11 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as ion channel modulators and methods of use
MX2007005857A (es) 2004-11-17 2007-10-10 Mikana Therapeutics Inc Inhibidores de cinasa.
WO2006068770A1 (en) 2004-11-24 2006-06-29 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
US20060128710A1 (en) * 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
CA2588220A1 (en) * 2004-12-23 2006-06-29 Pfizer Products Inc. Heteroaromatic derivatives useful as anticancer agents
US8110573B2 (en) * 2004-12-30 2012-02-07 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
EP1841760B1 (en) 2004-12-30 2011-08-10 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP2161275A1 (en) 2005-01-19 2010-03-10 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
AR054425A1 (es) * 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
EP1871765B1 (en) * 2005-01-26 2009-12-09 Schering Corporation 3-(indazol-5-yl)-(1,2,4)triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer
NZ561145A (en) 2005-02-04 2011-02-25 Astrazeneca Ab Pyrazolylaminopyridine derivatives useful as kinase inhibitors
AU2006215386B2 (en) 2005-02-16 2009-06-11 Astrazeneca Ab Chemical compounds
WO2006087538A1 (en) * 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
AU2006227790B2 (en) * 2005-03-15 2009-09-10 Irm Llc Compounds and compositions as protein kinase inhibitors
JP2008534481A (ja) * 2005-03-23 2008-08-28 ケă‚čăƒˆăƒ©ă‚Œăƒă‚« ă‚ąă‚Żăƒăƒœăƒ©ă‚° ă‚€ăƒłă‚čăƒȘăƒłæ§˜ćą—æź–ć› ć­âˆ’ïŒ‘ć—ćźčäœ“æŽ»æ€§ăźé˜»ćźłć‰€ăšă—ăŠăźïŒ’âˆ’ă‚ąă‚Œăƒă‚žăƒ‹ăƒ«âˆ’ïŒ”âˆ’ïŒˆïŒ‘ïœˆâˆ’ăƒ”ăƒ©ă‚ŸăƒŒăƒ«âˆ’ïŒ“âˆ’ă‚€ăƒ«ă‚ąăƒŸăƒŽïŒ‰ăƒ”ăƒȘミゾン
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
DE602006002271D1 (de) * 2005-04-05 2008-09-25 Astrazeneca Ab Pyrimidinderivate zur verwendung als antikrebsmittel
GB0507347D0 (en) * 2005-04-12 2005-05-18 Astrazeneca Ab Chemical compounds
US7462639B2 (en) 2005-04-14 2008-12-09 Hoffmann-La Roche Inc. Aminopyrazole derivatives
JP2008540335A (ja) * 2005-04-27 2008-11-20 ケă‚čăƒˆăƒ©ă‚Œăƒă‚«ăƒ»ă‚ąă‚Żăƒă‚šăƒœăƒ©ăƒŒă‚° ăƒ”ăƒ©ă‚ŸăƒȘăƒ«ăƒ»ăƒ”ăƒȘミゾンèȘ˜ć°Žäœ“ăźç–Œç—›æČ»ç™‚ă«ăŠă‘ă‚‹äœżç”š
JP5075624B2 (ja) * 2005-04-28 2012-11-21 田èŸșäž‰è±èŁœè–Źæ ȘćŒäŒšç€Ÿ ă‚·ă‚ąăƒŽăƒ”ăƒȘゾンèȘ˜ć°Žäœ“ćŠăłăăźćŒ»è–Źăšă—ăŠăźç”šé€”
WO2006119504A2 (en) 2005-05-04 2006-11-09 Renovis, Inc. Fused heterocyclic compounds, and compositions and uses thereof
WO2006117212A2 (en) 2005-05-04 2006-11-09 Develogen Aktiengesellschaft Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
US20080194606A1 (en) * 2005-05-05 2008-08-14 Astrazeneca Pyrazolyl-Amino-Substituted Pyrimidines and Their Use in the Treatment of Cancer
US20080287437A1 (en) * 2005-05-16 2008-11-20 Astrazeneca Ab Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7491732B2 (en) 2005-06-08 2009-02-17 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
JP5118029B2 (ja) 2005-06-14 2013-01-16 ă‚żă‚€ă‚Čン ăƒă‚€ă‚Șăƒ†ă‚ŻăƒŽăƒ­ă‚žăƒŒ ă‚«ăƒłăƒ‘ăƒ‹ăƒŒïŒŒăƒȘミテッド ピăƒȘăƒŸă‚žăƒłćŒ–ćˆç‰©
EP1746096A1 (en) 2005-07-15 2007-01-24 4Sc Ag 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
CA2619517A1 (en) * 2005-08-18 2007-02-22 Michael Mortimore Pyrazine kinase inhibitors
WO2007023382A2 (en) * 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
AU2006282896A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
UA96427C2 (en) * 2005-09-30 2011-11-10 МоĐčĐșĐ°ĐœĐ° ĐąĐ”Ń€Đ°ĐżŃŒŃŽŃ‚ĐžĐșс, Đ˜ĐœĐș. Substituted pyrazole compounds
WO2007041358A2 (en) * 2005-09-30 2007-04-12 Miikana Therapeutics, Inc. Substituted pyrazole compounds
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
RU2463302C2 (ru) * 2005-10-28 2012-10-10 ĐŃŃ‚Ń€Đ°Đ·Đ”ĐœĐ”ĐșĐ° Аб ĐŸŃ€ĐŸĐžĐ·ĐČĐŸĐŽĐœŃ‹Đ” 4-(3-Đ°ĐŒĐžĐœĐŸĐżĐžŃ€Đ°Đ·ĐŸĐ»)ĐżĐžŃ€ĐžĐŒĐžĐŽĐžĐœĐ° ĐŽĐ»Ń ĐżŃ€ĐžĐŒĐ”ĐœĐ”ĐœĐžŃ ĐČ ĐșачДстĐČĐ” ĐžĐœĐłĐžĐ±ĐžŃ‚ĐŸŃ€ĐŸĐČ Ń‚ĐžŃ€ĐŸĐ·ĐžĐœĐșĐžĐœĐ°Đ·Ń‹ ĐŽĐ»Ń Đ»Đ”Ń‡Đ”ĐœĐžŃ Đ·Đ»ĐŸĐșачДстĐČĐ”ĐœĐœĐŸĐłĐŸ ĐœĐŸĐČĐŸĐŸĐ±Ń€Đ°Đ·ĐŸĐČĐ°ĐœĐžŃ
JP2009513672A (ja) 2005-10-31 2009-04-02 ăƒ–ăƒŹă‚€ăƒłă‚»ăƒ«ă‚čïŒŒă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ă‚Łăƒ‰ 焞甌ç™șç”Ÿăźïœ‡ïœïœ‚ïœć—ćźč䜓ćȘ’介èȘżçŻ€
ATE521608T1 (de) * 2005-11-01 2011-09-15 Array Biopharma Inc Glucokinaseaktivatoren
JP5249770B2 (ja) * 2005-11-03 2013-07-31 ăƒăƒŒăƒ†ăƒƒă‚Żă‚č ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ă‚­ăƒŠăƒŒă‚Œă‚€ăƒłăƒ’ăƒ“ă‚żăƒŒăšă—ăŠæœ‰ç”šăȘケミノピăƒȘゾン
CA2629781A1 (en) * 2005-11-16 2007-05-24 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
JP5474354B2 (ja) 2005-12-30 2014-04-16 ケă‚čテックă‚čă€ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łăƒƒă‚Żă‚č、ăƒȘミテッド ćŒ»è–ŹćŒ–ćˆç‰©
US20080058312A1 (en) * 2006-01-11 2008-03-06 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c-Met activity
JO2660B1 (en) 2006-01-20 2012-06-17 Ù†ÙˆÙŰ§Ű±ŰȘÙŠŰł Ű§ÙŠÙ‡ ŰŹÙŠ Pi-3 inhibitors and methods of use
US7807672B2 (en) * 2006-02-16 2010-10-05 Schering Corporation Compounds that are ERK inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
PE20080145A1 (es) * 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
BRPI0709690B8 (pt) * 2006-03-30 2021-05-25 Janssen R & D Ireland 5-amido pirimidinas substituĂ­das e composição farmacĂȘutica que as compreende
MX2008012482A (es) * 2006-03-31 2008-10-10 Abbott Lab Compuestos de indazol.
EP2574340A3 (en) 2006-04-07 2013-04-17 Novartis AG Combination comprising a pyrimidylaminobenzamide compound and a THR315LLEe kinase inhibitor
NZ572591A (en) 2006-04-14 2012-01-12 Prana Biotechnology Ltd 3N-substituted 8-hydroxy-quinazolin-4-ones
EP2017279B1 (en) * 2006-04-27 2013-09-04 Msd K.K. Aminopyrimidine derivatives having aurora-a-selective inhibitory activity
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
JP4401428B2 (ja) 2006-06-27 2010-01-20 æ­Šç”°è–Źć“ć·„æ„­æ ȘćŒäŒšç€Ÿ çžźćˆç’°ćŒ–ćˆç‰©
WO2008001101A2 (en) * 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations
JP5523829B2 (ja) 2006-06-29 2014-06-18 ケă‚čテックă‚čă€ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łăƒƒă‚Żă‚č、ăƒȘミテッド è€‡ćˆè–Źć‰€
EP2036894A4 (en) * 2006-06-30 2011-01-12 Kyowa Hakko Kirin Co Ltd AURORA INHIBITOR
UY30444A1 (es) * 2006-06-30 2008-01-31 Astrazeneca Ab Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.
CA2656290A1 (en) 2006-07-05 2008-01-10 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
WO2008021038A2 (en) * 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
US7832809B2 (en) * 2006-08-11 2010-11-16 Schlumberger Technology Corporation Degradation assembly shield
JP2008081492A (ja) * 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd ă‚ȘăƒŒăƒ­ăƒ©ïœéžæŠžçš„é˜»ćźłäœœç”šă‚’æœ‰ă™ă‚‹æ–°èŠă‚ąăƒŸăƒŽăƒ”ăƒȘゾンèȘ˜ć°Žäœ“
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP2010505961A (ja) * 2006-10-09 2010-02-25 ă‚żă‚±ăƒ€ ă‚”ăƒł ディスギ ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ă‚­ăƒŠăƒŒă‚Œé˜»ćźłć‰€
JP2010505962A (ja) 2006-10-09 2010-02-25 æ­Šç”°è–Źć“ć·„æ„­æ ȘćŒäŒšç€Ÿ ă‚­ăƒŠăƒŒă‚Œé˜»ćźłć‰€
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
WO2008053812A1 (en) * 2006-10-27 2008-05-08 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and medicinal use thereof
EP2086965B1 (en) * 2006-11-02 2010-02-10 Vertex Pharmaceuticals, Inc. Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
DE602007007985D1 (de) * 2006-12-19 2010-09-02 Vertex Pharma Als inhibitoren von proteinkinasen geeignete aminopyrimidine
KR20090094073A (ko) * 2006-12-29 2009-09-03 티볮텍 파마슈티ìčŒìŠˆ 멬믾티드 넌 얔제하는 6-ìč˜í™˜ëœ í”ŒëŠŹëŻžë”˜
CN101573342A (zh) * 2006-12-29 2009-11-04 æł°ćšç‰čć…‹èŻć“æœ‰é™ć…Źćž æŠ‘ćˆ¶hiv的5,6-ć–ä»Łçš„ć˜§ć•¶ç±»ćŒ–ćˆç‰©
KR20090108124A (ko) 2007-02-06 2009-10-14 녞파넎티슀 아êȌ  3-킀나제 얔제제 및 귞의 ì‚Źìš© ë°©ëȕ
JPWO2008111441A1 (ja) 2007-03-05 2010-06-24 捔撌ç™ș酔キăƒȘンæ ȘćŒäŒšç€Ÿ ćŒ»è–Źç”„æˆç‰©
KR20090120510A (ko) * 2007-03-09 2009-11-24 ëČ„í…ìŠ€ 파마슈티ìčŒìŠ€ ìžìœ”íŹë ˆìŽí‹°ë“œ 닚백질 킀나제 ì–”ì œì œëĄœì„œ 유용한 ì•„ëŻžë…ží”ŒëŠŹëŻžë”˜
MX2009009592A (es) * 2007-03-09 2009-11-10 Vertex Pharma Aminopiridinas utiles como inhibidores de proteinas cinasas.
CA2679884A1 (en) * 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
CA2682195A1 (en) * 2007-03-20 2008-09-25 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
CA2683785A1 (en) * 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
WO2008129255A1 (en) * 2007-04-18 2008-10-30 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
WO2008129380A1 (en) 2007-04-18 2008-10-30 Pfizer Products Inc. Sulfonyl amide derivatives for the treatment of abnormal cell growth
JP5389786B2 (ja) * 2007-05-02 2014-01-15 ăƒăƒŒăƒ†ăƒƒă‚Żă‚č ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ă‚­ăƒŠăƒŒă‚Œé˜»ćźłăšă—ăŠæœ‰ç”šăȘケミノピăƒȘミゾン
AU2008247592A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
MX2009011811A (es) * 2007-05-02 2010-01-14 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasa.
ATE521609T1 (de) * 2007-05-04 2011-09-15 Astrazeneca Ab Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs
UA99459C2 (en) 2007-05-04 2012-08-27 ĐŃŃ‚Ń€Đ°Đ·Đ”ĐœĐ”ĐșĐ° Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
CN101687852A (zh) * 2007-05-24 2010-03-31 æČƒæł°ć…‹æ–ŻèŻç‰©è‚Ąä»œæœ‰é™ć…Źćž ćŻç”šäœœæż€é…¶æŠ‘ćˆ¶ć‰‚çš„ć™»ć”‘ç±»ć’ŒćĄć”‘ç±»ćŒ–ćˆç‰©
KR101294731B1 (ko) * 2007-06-04 2013-08-16 삌성디슀플레읎 ìŁŒì‹íšŒì‚Ź 얎레읎 Ʞ판, 읎넌 갖는 표시팚널 및 읎의 ì œìĄ°ë°©ëȕ
JP2010529193A (ja) * 2007-06-11 2010-08-26 ăƒŸă‚€ă‚«ăƒŠ ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łă‚Żă‚č ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ çœźæ›ăƒ”ăƒ©ă‚ŸăƒŒăƒ«ćŒ–ćˆç‰©
JP2010532756A (ja) * 2007-07-06 2010-10-14 ă‚ȘăƒŒă‚šă‚čă‚ąă‚€ăƒ»ăƒ•ă‚ĄăƒŒăƒžă‚čăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚șăƒ»ă‚€ăƒłă‚łăƒŒăƒăƒŹăƒŒăƒ†ăƒƒăƒ‰ ïœïŒŽïŒŻïŒČïŒŁïŒ‘ćŠăłïœïŒŽïŒŻïŒČïŒŁïŒ’ăźäžĄæ–čăźé˜»ćźłć‰€ă‚’ć«ă‚€ç”„ăżćˆă‚ă›æŠ—ç™Œç™‚æł•
WO2009007753A2 (en) * 2007-07-11 2009-01-15 Astrazeneca Ab 4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer
KR20100038108A (ko) * 2007-07-25 2010-04-12 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 íŠžëŠŹì•„ì§„ 킀나제 얔제제
WO2009013545A2 (en) * 2007-07-26 2009-01-29 Astrazeneca Ab Chemical compounds
TW200906818A (en) * 2007-07-31 2009-02-16 Astrazeneca Ab Chemical compounds
AU2008282156B2 (en) * 2007-07-31 2014-07-17 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009027736A2 (en) * 2007-08-27 2009-03-05 Astrazeneca Ab 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
EP3078662A1 (en) 2007-09-21 2016-10-12 Array Biopharma, Inc. Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
ES2445444T3 (es) 2007-10-11 2014-03-03 Glaxosmithkline Llc Nuevos inhibidores de sEH y su uso
TW200942549A (en) 2007-12-17 2009-10-16 Janssen Pharmaceutica Nv Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
US20090270418A1 (en) * 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
ES2556353T3 (es) 2008-02-21 2016-01-15 Merck Sharp & Dohme Corp. Compuestos que son inhibidores de las ERK
WO2009104802A1 (en) * 2008-02-22 2009-08-27 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
HUE025179T2 (en) 2008-04-21 2016-02-29 Taigen Biotechnology Co Ltd Heterocyclic Compounds
US8844033B2 (en) 2008-05-27 2014-09-23 The Trustees Of Columbia University In The City Of New York Systems, methods, and media for detecting network anomalies using a trained probabilistic model
AU2009259026B2 (en) * 2008-06-11 2012-10-04 Astrazeneca Ab Tricyclic 2,4-diamin0-L,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP2318377B1 (en) * 2008-07-31 2013-08-21 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
CN102215816A (zh) * 2008-09-03 2011-10-12 æČƒæł°ć…‹æ–ŻèŻç‰©è‚Ąä»œæœ‰é™ć…Źćž ć…±æ™¶ć’ŒćŒ…ć«æ‰€èż°ć…±æ™¶çš„èŻç‰©ćˆ¶ć‰‚
CN102405284B (zh) * 2008-09-05 2016-01-20 新ćŸșé˜żç»Žçœ—ç±łć…‹æ–Żç ”ç©¶ć…Źćž èźŸèźĄäžćŻé€†æŠ‘ćˆ¶ć‰‚çš„çź—æł•
CN102264728B (zh) * 2008-09-15 2015-02-04 ćŠ ćˆ©çŠć°Œäșšć€§ć­Šè‘Łäș‹äŒš 甹äșŽè°ƒèŠ‚ire1、src撌abl掻性的æ–čæł•ć’Œç»„ćˆç‰©
RU2011116928A (ru) * 2008-09-30 2012-11-20 ĐŃŃ‚Ń€Đ°Đ·Đ”ĐœĐ”ĐșĐ° Аб (Se) Đ“Đ”Ń‚Đ”Ń€ĐŸŃ†ĐžĐșлОчДсĐșОД ĐžĐœĐłĐžĐ±ĐžŃ‚ĐŸŃ€Ń‹ jĐ°Đș ĐșĐžĐœĐ°Đ·Ń‹
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
WO2010056758A1 (en) * 2008-11-12 2010-05-20 Yangbo Feng Quinazoline derivatives as kinase inhibitors
US9023834B2 (en) 2008-11-13 2015-05-05 Taigen Biotechnology Co., Ltd. Lyophilization formulation
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
PA8851101A1 (es) 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol
JP5490137B2 (ja) * 2008-12-19 2014-05-14 ăƒăƒ«ăƒ“ă‚ąăƒŒăƒŽăƒ»ăƒĄăƒ‡ă‚€ă‚«ăƒ«ăƒ»ă‚”ă‚€ă‚šăƒłă‚·ăƒŒă‚șăƒ»ă‚šăƒ„ă‚»ăƒ»ă‚šăƒ«ăƒŹăƒ»ă‚šăƒ«ăƒŹ ăƒ—ăƒ­ăƒ†ă‚€ăƒłă‚­ăƒŠăƒŒă‚Œé˜»ćźłè–Źăšă—ăŠăźäșŒç’°ćŒăƒ”ăƒ©ă‚ŸăƒŒăƒ«
JP5738196B2 (ja) 2008-12-22 2015-06-17 ミレニケム ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ïŒ­ïœ‰ïœŒïœŒïœ…ïœŽïœŽïœ‰ïœ•ïœ   ă‚ȘăƒŒăƒ­ăƒ©ă‚­ăƒŠăƒŒă‚Œé˜»ćźłć‰€ăŠă‚ˆăłæŠ—ïœƒïœ„ïŒ’ïŒæŠ—äœ“ăźäœ”ç”š
US8809343B2 (en) 2008-12-26 2014-08-19 Fudan University Pyrimidine derivative, preparation method and use thereof
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN102395576A (zh) * 2009-02-27 2012-03-28 ćŸƒć§†æŻ”ç‰čç”Ÿç‰©ç§‘ć­Šć…Źćž 调控jakæż€é…¶çš„ć–čć”‘ć•‰èĄç”Ÿç‰©ć’Œć…¶äœżç”šæ–čæł•
CA2660962A1 (en) 2009-03-31 2010-09-30 Astellas Pharma Inc. Novel pharmaceutical composition for treatment of schizophrenia
US8399663B2 (en) 2009-04-03 2013-03-19 Astellas Pharma Inc. Salt of 1,3,5-triazine-2,4,6-triamine derivative
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc Ù…Ű±ÙƒŰšŰ§ŰȘ Ű”ÙŠŰŻÙ„Ű§Ù†ÙŠŰ© Ű”Ù„ŰšŰ© ÙˆŰ·Ű±Ù‚ Ù„Ű§Ù†ŰȘŰ§ŰŹÙ‡Ű§
JP2012529513A (ja) * 2009-06-08 2012-11-22 ă‚ąăƒ–ăƒ©ă‚Żă‚·ă‚č ăƒă‚€ă‚Șă‚”ă‚€ă‚šăƒłă‚č ăƒȘミテッド ăƒ©ă‚€ă‚ąăƒ“ăƒȘăƒ†ă‚ŁăƒŒ ă‚«ăƒłăƒ‘ăƒ‹ăƒŒ トăƒȘケゾンèȘ˜ć°Žäœ“éĄžćŠăłăă‚Œă‚‰ăźæČ»ç™‚ćżœç”š
CA2764785C (en) * 2009-06-08 2015-10-27 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
US20120178758A1 (en) * 2009-06-09 2012-07-12 California Capital Equity, Llc Styryl-triazine derivatives and their therapeutical applications
US9078902B2 (en) 2009-06-09 2015-07-14 Nantbioscience, Inc. Triazine derivatives and their therapeutical applications
BRPI1011527A2 (pt) * 2009-06-09 2016-07-26 California Capital Equity Llc derivados de triazina substituĂ­dos com ureidofenil e suas aplicaçÔes terapĂȘuticas.
US8877924B2 (en) 2009-06-09 2014-11-04 NantBio Inc. Benzyl substituted triazine derivatives and their therapeutical applications
CA2763730A1 (en) * 2009-06-18 2010-12-23 Cellzome Limited Heterocyclylaminopyrimidines as kinase inhibitors
TWI468402B (zh) * 2009-07-31 2015-01-11 濅æČ»ćŠ„çŸŽé›…ćČè°·æŻ”ć…Źćž 降䜎ÎČïŒéĄžæŸ±çČ‰ç”Ÿæˆäč‹ćŒ–ćˆç‰©
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromåticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
EP2478361A4 (en) * 2009-09-16 2014-05-21 Celgene Avilomics Res Inc CONJUGATES AND INHIBITORS OF PROTEIN KINASE
EP2467065B1 (en) * 2009-11-13 2020-01-08 Intuitive Surgical Operations, Inc. End effector with redundant closing mechanisms
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
CN102812167A (zh) 2009-12-30 2012-12-05 é˜żç»Žæ‹‰ćˆ¶èŻć…Źćž 蛋癜的配䜓-ä»‹ćŻŒçš„ć…±ä»·äżźé„°
SA111320200B1 (ar) * 2010-02-17 2014-02-16 ŰŻÙŠŰšÙŠÙˆÙŰ§Ű±Ù… ۧ۳ Ű§ÙŠÙ‡ Ù…Ű±ÙƒŰšŰ§ŰȘ Ű«Ù†Ű§ŰŠÙŠŰ© Ű§Ù„Ű­Ù„Ù‚Ű© ÙˆŰ§ŰłŰȘŰźŰŻŰ§Ù…Ű§ŰȘÙ‡Ű§ ÙƒÙ…Ű«ŰšŰ·Ű§ŰȘ c-src/jak مŰČŰŻÙˆŰŹŰ©
RU2012140021A (ru) 2010-02-19 2014-03-27 ĐœĐžĐ»Đ»Đ”ĐœĐžŃƒĐŒ Đ€Đ°Ń€ĐŒĐ°ŃŃŒŃŽŃ‚ĐžĐșалз, Đ˜ĐœĐș. КРИСбАЛЛИЧЕСКИЕ Đ€ĐžĐ ĐœĐ« 4-{[9-ЄЛОР-7-(2-ЀйОР-6-ĐœĐ•ĐąĐžĐšĐĄĐ˜Đ€Đ•ĐĐ˜Đ›)-5Н-ПИРИМИДО[5,4-d][2]БЕНЗАЗЕПИН-2-ИЛ]АМИНО}-2-МЕбОКСИБЕНЗОАбА НАбРИЯ
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2571359A4 (en) * 2010-05-20 2013-10-23 Merck Sharp & Dohme NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
JP5607241B2 (ja) 2010-05-21 2014-10-15 ă‚±ăƒŸăƒȘă‚ąăƒ»ă‚šăƒŒăƒ“ăƒŒ æ–°èŠăƒ”ăƒȘミゾンèȘ˜ć°Žäœ“
HUE029196T2 (en) 2010-06-04 2017-02-28 Hoffmann La Roche Aminoprimidine derivatives as LRRK2 modulators
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
ME03085B (me) 2010-07-29 2019-01-20 Oryzon Genomics Sa Demetilaza inhibitori lsd1 zasnovani na arilciklopropilaminu i njihova medicinska primjena
WO2012030910A1 (en) * 2010-09-01 2012-03-08 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
JP5932794B2 (ja) 2010-09-01 2016-06-08 ケムビト ビă‚Șă‚čă‚·ă‚šăƒłă‚»ă‚č ă‚łăƒ«ăƒăƒ©ăƒă‚Șン ć…‰ć­ŠæŽ»æ€§ăźă‚ă‚‹ăƒ”ăƒ©ă‚ŸăƒȘăƒ«ă‚ąăƒŸăƒŽă‚­ăƒŠă‚ŸăƒȘăƒłćŠăłăăźćŒ»è–Źç”„æˆç‰©ćŠăłäœżç”šæ–čæł•
US20120053176A1 (en) * 2010-09-01 2012-03-01 Ambit Biosciences Corp. Adenosine a3 receptor modulating compounds and methods of use thereof
CN103270030B (zh) * 2010-09-01 2016-01-20 ćŸƒć§†æŻ”ç‰čç”Ÿç‰©ç§‘ć­Šć…Źćž 搡攑ćŸșæ°šćŸșć–čć”‘ć•‰çš„æ°ąæșŽé…žç›
US20130225614A1 (en) * 2010-09-01 2013-08-29 Ambit Biosciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
CA2810024A1 (en) * 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
WO2012030944A2 (en) * 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinoline and isoquinoline compounds and methods of use thereof
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
BR112013011600B1 (pt) 2010-11-10 2022-01-11 Genentech, Inc Derivados de pirazol aminopirimidina, seu uso e composição que os compreende
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2688883B1 (en) 2011-03-24 2016-05-18 Noviga Research AB Pyrimidine derivatives
JP2014524456A (ja) 2011-08-25 2014-09-22 ă‚šăƒ•ăƒ»ăƒ›ăƒ•ăƒžăƒłâˆ’ăƒ©ăƒ»ăƒ­ă‚·ăƒ„ăƒ»ă‚ąă‚Żăƒă‚§ăƒłă‚Čă‚Œăƒ«ă‚·ăƒŁăƒ•ăƒˆ ă‚»ăƒȘăƒłïŒă‚čハă‚Șăƒ‹ăƒłïœïœïœ‹ïŒ‘é˜»ćźłć‰€
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PE20141228A1 (es) 2011-09-22 2014-10-01 Pfizer Derivados de pirrolopirimidina y purina
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2822935B1 (en) 2011-11-17 2019-05-15 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
WO2013092940A1 (en) 2011-12-22 2013-06-27 F. Hoffmann-La Roche Ag 2, 4-diamine-pyrimidine derivative as serine/threonine kinase inhibitors
CN104203939B (zh) * 2012-02-17 2017-06-06 è‰ŸäŒŻç»Žć…Źćž 甚䜜äșșć‘Œćžé“ćˆèƒžç—…æŻ’ïŒˆrsvïŒ‰æŠ‘ćˆ¶ć‰‚çš„äșŒæ°šćŸșć˜§ć•¶
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
TWI485146B (zh) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof
MX2014011115A (es) 2012-03-16 2015-03-13 Axikin Pharmaceuticals Inc Inhibidores de 3,5-diaminopirazol cinasa.
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
RS61664B1 (sr) 2012-04-24 2021-04-29 Vertex Pharma Inhibitori dna-pk
CA2875990A1 (en) * 2012-05-24 2013-11-28 Cellzome Limited Heterocyclyl pyrimidine analogues as tyk2 inhibitors
JP6280546B2 (ja) 2012-06-26 2018-02-14 ăƒ‡ăƒ« ăƒžăƒŒ ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ă‚žă‚ąăƒłăƒ’ăƒ‰ăƒ­ă‚Źăƒ©ă‚ŻăƒăƒˆăƒŒăƒ«ă€ă‚žă‚ąă‚»ăƒăƒ«ă‚žă‚ąăƒłăƒ’ăƒ‰ăƒ­ă‚Źăƒ©ă‚ŻăƒăƒˆăƒŒăƒ«ă€ă‚žăƒ–ăƒ­ăƒąă‚șăƒ«ă‚·ăƒˆăƒŒăƒ«ă€ćˆăŻă“ă‚Œă‚‰ăźéĄžäŒŒäœ“è‹„ă—ăăŻèȘ˜ć°Žäœ“ă‚’ç”šă„ăŸă€éșäŒć­ć€šćž‹ćˆăŻïœïœˆïœ‰ïŒ‘ăźèȘżçŻ€äžć…šè‹„ă—ăăŻć€‰ç•°ă‚’æœ‰ă™ă‚‹æ‚Łè€…ă«ăŠă‘ă‚‹ăƒăƒ­ă‚·ăƒłă‚­ăƒŠăƒŒă‚Œă‚€ăƒłăƒ’ăƒ“ă‚żăƒŒæŠ”æŠ—æ€§æ‚Șæ€§è…«ç˜ă‚’ć‡Šçœźă™ă‚‹ăŸă‚ăźæ–čæł•
CA2878621C (en) * 2012-07-10 2020-09-15 Ares Trading S.A. Pyrimidine pyrazolyl derivatives
US9555115B2 (en) * 2012-09-19 2017-01-31 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration with improved dissolution and/or absorption
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
CN103191120B (zh) * 2012-12-31 2015-11-25 战ćŒș äž€ç§ć˜§ć•¶èĄç”Ÿç‰©ćœšćˆ¶ć€‡éą„é˜Č撌/或æČ»ç–—ć’Œ/æˆ–èŸ…ćŠ©æČ»ç–—è‚żç˜€çš„èŻç‰©äž­çš„ç”šé€”
CN103202843B (zh) * 2012-12-31 2015-04-29 战ćŒș äž€ç§ć˜§ć•¶èĄç”Ÿç‰©ćœšćˆ¶ć€‡éą„é˜Č撌/或æČ»ç–—ć’Œ/æˆ–èŸ…ćŠ©æČ»ç–—ç™Œç—‡çš„èŻç‰©äž­çš„ç”šé€”
CN103059002B (zh) * 2012-12-31 2015-04-22 䞭汱性歊 ć…·æœ‰Auroraæż€é…¶æŠ‘ćˆ¶æŽ»æ€§çš„ć˜§ć•¶èĄç”Ÿç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•ä»„ćŠćș”甚
CN103910716A (zh) * 2013-01-07 2014-07-09 ćŽäžœç†ć·„ć€§ć­Š 2,4-äșŒć–代-çŽŻçƒ·ćŸș[d]ć˜§ć•¶ç±»ćŒ–ćˆç‰©ćŠć…¶ç”šé€”
SI3527563T1 (sl) 2013-03-12 2022-01-31 Vertex Pharmaceuticals Incorporated Inhibitorji DNA-PK
PE20151939A1 (es) 2013-03-14 2016-01-08 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
EP2968322B1 (en) 2013-03-15 2018-12-26 The Trustees of Columbia University in the City of New York Map kinase modulators and uses thereof
JP6360881B2 (ja) 2013-03-22 2018-07-18 ミレニケム ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ïŒ­ïœ‰ïœŒïœŒïœ…ïœŽïœŽïœ‰ïœ•ïœ   觊ćȘ’çš„ïœïœ”ïœïœ’ïœƒïŒ‘ïŒïŒ’é˜»ćźłè–ŹćŠăłă‚ȘăƒŒăƒ­ăƒ©ïœă‚­ăƒŠăƒŒă‚ŒăźéžæŠžçš„é˜»ćźłè–Źăźç”„ćˆă›
WO2015003355A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
KR20160099081A (ko) 2013-07-26 2016-08-19 업데읎튞 파마 ìžìœ”íŹë ˆìŽíŠž ëč„산튞렌의 ìč˜ëŁŒ íššêłŒ 개선용 ìĄ°í•© ë°©ëȕ
WO2015028848A1 (en) * 2013-09-02 2015-03-05 Piramal Enterprises Limited Bicyclic heterocyclic compounds as multi-kinase inhibitors
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
SI3424920T1 (sl) 2013-10-17 2020-08-31 Vertex Pharmaceuticals Incorporated Kokristali (s)-n-metil-8-(1-((2'-metil-(4,5'-bipirimidin)-6-il)amino)propan-2-il) kinolin-4-karboksamida in devterirani derivati le-teh kot inhibitorji dna-pk
ES2676734T3 (es) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Compuestos heteroatĂłmicos Ăștiles para el tratamiento de enfermedades proliferativas
EP3057956B1 (en) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015103355A1 (en) 2014-01-01 2015-07-09 Medivation Technologies, Inc. Compounds and methods of use
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
EP3777833B1 (en) 2014-03-13 2023-10-18 Neuroderm Ltd. Dopa decarboxylase inhibitor compositions
JP6517319B2 (ja) 2014-03-28 2019-05-22 キャăƒȘă‚żăƒŒăƒ»ă‚”ă‚€ă‚šăƒłă‚·ăƒŒă‚ș・ăƒȘăƒŸăƒ†ăƒƒăƒ‰ăƒ»ăƒ©ă‚€ă‚ąăƒ“ăƒȘăƒ†ă‚Łăƒ»ă‚«ăƒłăƒ‘ăƒ‹ăƒŒïŒŁïœïœŒïœ‰ïœ”ïœïœ’ ïŒłïœƒïœ‰ïœ…ïœŽïœƒïœ…ïœ“ïŒŒ ïŒŹïœŒïœƒ çœźæ›ă•ă‚ŒăŸăƒ˜ăƒ†ăƒ­ă‚ąăƒȘăƒŒăƒ«ćŒ–ćˆç‰©ăŠă‚ˆăłäœżç”šæ–čæł•
MA39840B1 (fr) 2014-04-04 2020-10-28 Iomet Pharma Ltd DĂ©rivĂ©s indolĂ©s destinĂ©s Ă  ĂȘtre utilisĂ©s dans le domaine de la mĂ©decine
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
CN105367555B (zh) * 2014-08-07 2019-06-25 ćčżäžœäžœé˜łć…‰èŻäžšæœ‰é™ć…Źćž ć–ä»Łçš„æ‚èŠłćŸșćŒ–ćˆç‰©ćŠć…¶ç»„ćˆç‰©ć’Œç”šé€”
HRP20250213T1 (hr) 2014-10-13 2025-04-25 Yuhan Corporation Spojevi i pripravci za modulaciju aktivnosti egfr mutantne kinaze
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2016123627A1 (en) * 2015-01-30 2016-08-04 Vanderbilt University Isoquiniline and napthalene-substituted compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
AU2016247858B2 (en) 2015-04-17 2020-10-15 Ludwig Institute For Cancer Research Ltd. PLK4 inhibitors
DK3303348T3 (da) 2015-05-28 2019-11-11 Theravance Biopharma R&D Ip Llc Naphthyridinforbindelser som JAK-kinaseinhibitorer
JP2018135268A (ja) * 2015-06-05 2018-08-30 ć€§æ—„æœŹäœć‹èŁœè–Źæ ȘćŒäŒšç€Ÿ æ–°èŠăƒ˜ăƒ†ăƒ­ă‚ąăƒȘăƒŒăƒ«ă‚ąăƒŸăƒŽâˆ’ïŒ“âˆ’ăƒ”ăƒ©ă‚ŸăƒŒăƒ«èȘ˜ć°Žäœ“ăŠă‚ˆăłăăźè–Źç†ć­ŠäžŠèš±ćźčă•ă‚Œă‚‹ćĄ©
US20180207173A1 (en) 2015-07-21 2018-07-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
JP7028766B2 (ja) 2015-09-09 2022-03-02 ăƒ€ăƒŠïŒăƒ•ă‚ĄăƒŒăƒăƒŒ ă‚­ăƒŁăƒłă‚”ăƒŒ ă‚€ăƒłă‚čăƒ†ă‚Łăƒ†ăƒ„ăƒŒăƒˆïŒŒ ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ゔむクăƒȘăƒłäŸć­˜æ€§ă‚­ăƒŠăƒŒă‚Œăźé˜»ćźłć‰€
US9938257B2 (en) 2015-09-11 2018-04-10 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
EA201800367A1 (ru) * 2015-12-10 2019-02-28 ПобоСо бЕРАПЬмбИКС, ИНК. ĐĄĐżĐŸŃĐŸĐ±Ń‹ Đ»Đ”Ń‡Đ”ĐœĐžŃ Đ±ĐŸĐ»Đ”Đ·ĐœĐž Ń…Đ°ĐœŃ‚ĐžĐœĐłŃ‚ĐŸĐœĐ°
CN105384702B (zh) * 2015-12-11 2018-04-10 æ”™æ±Ÿć€§ć­Š äž‰ć–ä»Łć‡äž‰ć—Șç±»ćŒ–ćˆç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•
CN105399695B (zh) * 2015-12-11 2019-04-19 æ”™æ±Ÿć€§ć­Š 侉ć—Șç±»ćŒ–ćˆç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œç”šé€”
CN105503754B (zh) * 2015-12-11 2017-11-17 æ”™æ±Ÿć€§ć­Š 2‑氚ćŸș‑4‑苄ćŸș‑6‑搗敉‑1,3,5‑侉ć—ȘćŠć…¶ćˆ¶ć€‡ć’Œćș”甚
US10894784B2 (en) 2015-12-18 2021-01-19 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
AU2017233841B9 (en) 2016-03-14 2021-09-09 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
KR102377805B1 (ko) 2016-03-25 2022-03-22 애퍌런튞 íŒŒë§ˆìŠˆí‹°ì»ŹìŠ€ ìžíŹ. í”ŒëŠŹëŻžë”˜ 및 귞의 ëł€ìŽìČŽ, 및 귞의 용도
AU2017258186B2 (en) 2016-04-28 2020-09-17 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as JAK kinase inhibitors
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
KR20190062485A (ko) 2016-09-27 2019-06-05 ëČ„í…ìŠ€ 파마슈티ìčŒìŠ€ ìžìœ”íŹë ˆìŽí‹°ë“œ Dna-손상제 및 dna-pk 저핎제의 ìĄ°í•©ì„ ì‚Źìš©í•œ 암 ìč˜ëŁŒ ë°©ëȕ
US10858319B2 (en) 2016-10-03 2020-12-08 Iomet Pharma Ltd. Indole derivatives for use in medicine
WO2018089546A1 (en) * 2016-11-08 2018-05-17 Vanderbilt University Isoquinoline ether compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
CN108239071B (zh) * 2016-12-27 2020-12-04 æČˆé˜łèŻç§‘ć€§ć­Š 酰èƒșćŠçĄ«ä»Łé…°èƒșç±»èĄç”Ÿç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œćș”甚
FR3064275B1 (fr) 2017-03-21 2019-06-07 Arkema France Procede de chauffage et/ou climatisation d'un vehicule
AU2018278714B2 (en) 2017-05-30 2022-06-02 Basf Se Pyridine and pyrazine compounds
KR20200033249A (ko) 2017-06-05 2020-03-27 플티씚 테띌퓚틱슀, ìžíŹ. 헌팅턮병 ìč˜ëŁŒ í™”í•©ëŹŒ
US11395822B2 (en) 2017-06-28 2022-07-26 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
CA3067591A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
ES2969536T3 (es) 2017-06-30 2024-05-21 Beijing Tide Pharmaceutical Co Ltd Inhibidor de la proteína cinasa asociada a rho, composición farmacéutica que lo comprende, y su método de preparación y uso
JP2020525525A (ja) * 2017-06-30 2020-08-27 ăƒ™ă‚€ă‚žăƒł ă‚żă‚€ăƒ‰ ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ« ă‚«ăƒłăƒ‘ăƒ‹ăƒŒ ăƒȘăƒŸăƒ†ăƒƒăƒ‰ïŒąïœ…ïœ‰ïœŠïœ‰ïœŽïœ‡   ïŒŁïœïŒŽïŒŒ ïŒŹïœ”ïœ„ïŒŽ ïŒČïœˆïœâˆ’é–ąé€Łăƒ—ăƒ­ăƒ†ă‚€ăƒłă‚­ăƒŠăƒŒă‚Œé˜»ćźłć‰€ă€ïœ’ïœˆïœâˆ’é–ąé€Łăƒ—ăƒ­ăƒ†ă‚€ăƒłă‚­ăƒŠăƒŒă‚Œé˜»ćźłć‰€ă‚’ć«ă‚€ćŒ»è–Źç”„æˆç‰©ă€ćœ“è©ČćŒ»è–Źç”„æˆç‰©ăźèȘżèŁœæ–čæł•ćŠăłäœżç”š
WO2019000683A1 (zh) 2017-06-30 2019-01-03 挗äșŹæł°ćŸ·ćˆ¶èŻè‚Ąä»œæœ‰é™ć…Źćž Rhoç›žć…łè›‹ç™œæż€é…¶æŠ‘ćˆ¶ć‰‚ă€ćŒ…ć«ć…¶çš„èŻç‰©ç»„ćˆç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œç”šé€”
EP3676264A1 (en) * 2017-08-28 2020-07-08 Acurastem Inc. Pikfyve kinase inhibitors
CN111683662B (zh) * 2017-08-28 2024-04-02 陈濗漏 ć–ä»Łć˜§ć•¶ç±»ćŒ–ćˆç‰©ćŠć…¶èŻç‰©ç»„ćˆç‰©ć’ŒæȻ疗æ–čæł•
AU2018354370B2 (en) 2017-10-27 2023-04-27 Theravance Biopharma R&D Ip, Llc Pyrimidine compound as JAK kinase inhibitor
CA3076444A1 (en) * 2017-11-23 2019-05-31 Biomed X Gmbh Pyrimidine derivatives as tropomyosin receptor kinase a (trka) inhibitors
EP3720560A4 (en) * 2017-12-06 2022-01-05 Ludwig Institute for Cancer Research Ltd METHOD OF TREATMENT OF CANCER WITH PLK4 INHIBITORS
CA3093802A1 (en) 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
US12103926B2 (en) 2018-03-27 2024-10-01 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
AU2019295632B2 (en) * 2018-06-25 2025-03-06 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
EA202092899A1 (ru) 2018-06-27 2021-05-14 ПобоСо бЕРАПЬмбИКС, ИНК. Đ“Đ”Ń‚Đ”Ń€ĐŸĐ°Ń€ĐžĐ»ŃŒĐœŃ‹Đ” ŃĐŸĐ”ĐŽĐžĐœĐ”ĐœĐžŃ ĐŽĐ»Ń Đ»Đ”Ń‡Đ”ĐœĐžŃ Đ±ĐŸĐ»Đ”Đ·ĐœĐž ĐłĐ”ĐœŃ‚ĐžĐœĐłŃ‚ĐŸĐœĐ°
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
BR112020026545A2 (pt) 2018-06-27 2021-03-23 Ptc Therapeutics, Inc. Compostos heterocíclicos e de heteroarila para o tratamento da doença de huntington
MX2021006283A (es) * 2018-11-30 2021-10-22 Jiangsu Hansoh Pharmaceutical Group Co Ltd Derivados heteroaromåticos para uso como regulador, método de preparación de los mismos y uso de los mismos.
JP7660063B2 (ja) 2018-12-28 2025-04-10 ăƒ€ăƒŠïŒăƒ•ă‚ĄăƒŒăƒăƒŒ ă‚­ăƒŁăƒłă‚”ăƒŒ ă‚€ăƒłă‚čăƒ†ă‚Łăƒ†ăƒ„ăƒŒăƒˆïŒŒ ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ゔむクăƒȘăƒłäŸć­˜æ€§ă‚­ăƒŠăƒŒă‚ŒïŒ—ăźă‚€ăƒłăƒ’ăƒ“ă‚żăƒŒăŠă‚ˆăłăă‚Œă‚‰ăźäœżç”š
AR118768A1 (es) 2019-04-24 2021-10-27 Theravance Biopharma R&D Ip Llc Derivados de pirimidina como inhibidores de las cinasas jak
HRP20241053T1 (hr) 2019-04-24 2024-11-08 Theravance Biopharma R&D Ip, Llc Pirimidinski inhibitori jak, namijenjeni liječenju koĆŸnih bolesti
KR20220042159A (ko) 2019-08-01 2022-04-04 읞테귞랄 ë°”ìŽì˜€ì‚ŹìŽì–žìŠ€ 플람읎티. 엘티디. 킀나제 ì–”ì œì œëĄœì„œì˜ í—€í…ŒëĄœì‚ŹìŽíŽëŠ­ í™”í•©ëŹŒ 및 읎의 용도
CN114667289B (zh) 2019-09-18 2025-08-26 æ­Šç”°èŻć“ć·„äžšæœ‰é™ć…Źćž æ‚èŠłćŸșèĄ€æ”†æż€è‚œé‡Šæ”Ÿé…¶æŠ‘ćˆ¶ć‰‚
ES2987744T3 (es) 2019-09-18 2024-11-18 Takeda Pharmaceuticals Co Inhibidores de calicreĂ­na plasmĂĄtica y usos de los mismos
CN110483493A (zh) * 2019-09-19 2019-11-22 ćčżäžœć·„䞚性歊 侀种äșŒć”‘ç±»èĄç”Ÿç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œćș”甚
CN115209952B (zh) 2020-01-13 2025-05-30 绎ćŸșćˆ†æžæœ‰é™ć…Źćž ç»ć–ä»Łçš„ćĄć”‘ćč¶ć˜§ć•¶ćŠć…¶ç”šé€”
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
TW202237119A (zh) 2020-12-10 2022-10-01 çŸŽć•†äœć‹èŁœè—„è…«ç˜€ć…Źćž ïŒĄïœŒïœ‹ïč˜ïŒ•æŠ‘ćˆ¶ćŠ‘ć’ŒćœŒäč‹ç”šé€”
US20240199613A1 (en) * 2021-03-17 2024-06-20 Takeda Pharmaceutical Company Limited Polycyclic inhibitors of plasma kallikrein
WO2022204721A1 (en) * 2021-03-26 2022-09-29 Sumitomo Pharma Oncology, Inc. Alk-5 inhibitors and uses thereof
EP4337198A4 (en) 2021-05-11 2025-04-16 Oric Pharmaceuticals, Inc. POLO-TYPE 4 KINASE INHIBITORS
CA3223223A1 (en) 2021-06-28 2023-01-05 Blueprint Medicines Corporation Cdk2 inhibitors
KR102692529B1 (ko) * 2021-07-01 2024-08-08 한ꔭ원자렄의학원 Mastl-pp2aë„Œ 표적화하는 암의 예방 또는 ìč˜ëŁŒìš© 앜학적 ìĄ°ì„±ëŹŒ
CN116354938B (zh) * 2021-12-28 2024-02-20 æČˆé˜łèŻç§‘ć€§ć­Š 䞀类ć–čć”‘ć•‰èĄç”Ÿç‰©äžŽć…¶ç±»äŒŒç‰©çš„ćˆ¶ć€‡æ–čæł•ćŠćș”甚
CN114276302B (zh) * 2022-01-11 2023-07-25 ć±±äžœç™ŸćŻç”Ÿç‰©ćŒ»èŻæœ‰é™ć…Źćž äž€ç§ćˆ¶ć€‡2,4-äșŒæ°šćŸșć–čć”‘ć•‰èĄç”Ÿç‰©çš„æ–čæł•
CN116813595B (zh) * 2022-03-28 2025-07-18 äžŠæ”·ćŒ»èŻć·„äžšç ”ç©¶é™ąæœ‰é™ć…Źćž ć–čć”‘ć•‰ç±»èĄç”Ÿç‰©ă€ć…¶ćˆ¶ć€‡æ–čæł•ă€èŻç‰©ç»„ćˆç‰©ćŠćș”甚
WO2024003773A1 (en) 2022-07-01 2024-01-04 Pfizer Inc. 2,7-naphthyridine compounds as mastl inhibitors
CN117736198A (zh) * 2022-09-21 2024-03-22 科蟉æ™șèŻç”Ÿç‰©ç§‘æŠ€(æ·±ćœł)æœ‰é™ć…Źćž ć€§çŽŻć«æ°źć† é†šćŒ–ćˆç‰©ćŠć…¶äœœäžșè›‹ç™œæż€é…¶æŠ‘ćˆ¶ć‰‚çš„ćș”甚
CN115403568B (zh) * 2022-09-21 2023-09-29 䞭汱性歊 侀种ć–č攑敉类Aurora Ać…±ä»·æŠ‘ćˆ¶ć‰‚ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œćș”甚
AU2024226381A1 (en) * 2023-02-23 2025-10-09 Accutar Biotechnology, Inc. Novel macrocyclic aminopyrazole compounds as cdk2 inhibitors
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2585906A (en) 1952-02-12 Quaternary salts of pyrimdjines
US18436A (en) * 1857-10-20 And saml
US3133081A (en) * 1964-05-12 J-aminoindazole derivatives
US3935183A (en) * 1970-01-26 1976-01-27 Imperial Chemical Industries Limited Indazole-azo phenyl compounds
BE754242A (fr) * 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
US3998951A (en) * 1974-03-13 1976-12-21 Fmc Corporation Substituted 2-arylquinazolines as fungicides
DE2458965C3 (de) * 1974-12-13 1979-10-11 Bayer Ag, 5090 Leverkusen 3-Amino-indazol-N-carbonsÀure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel
MA18829A1 (fr) 1979-05-18 1980-12-31 Ciba Geigy Ag Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique
DOP1981004033A (es) * 1980-12-23 1990-12-29 Ciba Geigy Ag Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas.
SE8102194L (sv) * 1981-04-06 1982-10-07 Pharmacia Ab Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna
SE8102193L (sv) * 1981-04-06 1982-10-07 Pharmacia Ab Terapeutiskt aktiv organisk forening och dess anvendning
JPS58124773A (ja) 1982-01-20 1983-07-25 Mitsui Toatsu Chem Inc ïŒ•âˆ’ăƒĄăƒăƒ«ăƒă‚ȘピăƒȘミゾンèȘ˜ć°Žäœ“ăšăăźèŁœé€ æł•ăšèŸČćœ’èŠžç”šæźșèŒć‰€
EP0136976A3 (de) 1983-08-23 1985-05-15 Ciba-Geigy Ag Verwendung von Phenylpyrimidinen als Pflanzenregulatoren
DE3725638A1 (de) 1987-08-03 1989-02-16 Bayer Ag Neue aryloxy (bzw. thio)aminopyrimidine
JPH0532662A (ja) 1990-11-09 1993-02-09 Nissan Chem Ind Ltd çœźæ›ăƒ”ăƒ©ă‚ŸăƒŒăƒ«èȘ˜ć°Žäœ“ăŠă‚ˆăłèŸČćœ’èŠžç”šæźșèŒć‰€
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5714493A (en) * 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5597920A (en) 1992-04-30 1997-01-28 Neurogen Corporation Gabaa receptor subtypes and methods for screening drug compounds using imidazoquinoxalines and pyrrolopyrimidines to bind to gabaa receptor subtypes
JPH0665237A (ja) * 1992-05-07 1994-03-08 Nissan Chem Ind Ltd çœźæ›ăƒ”ăƒ©ă‚ŸăƒŒăƒ«èȘ˜ć°Žäœ“ăŠă‚ˆăłèŸČćœ’èŠžç”šæźșèŒć‰€
AU693114B2 (en) 1993-10-01 1998-06-25 Novartis Ag Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof
WO1996014843A2 (en) 1994-11-10 1996-05-23 Cor Therapeutics, Inc. Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
IL117659A (en) * 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
US5935966A (en) 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
CA2230896A1 (en) 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
JPH10130150A (ja) 1996-09-05 1998-05-19 Dainippon Pharmaceut Co Ltd 酱酾ケミドèȘ˜ć°Žäœ“からăȘă‚‹ćŒ»è–Ź
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
AU720135B2 (en) 1996-10-02 2000-05-25 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
AU738341B2 (en) 1996-10-11 2001-09-13 Abbott Gmbh & Co. Kg Asparate ester inhibitors of interleukin-1beta converting enzyme
DE19710435A1 (de) * 1997-03-13 1998-09-17 Hoechst Ag Verwendung von Pyrimidinderivaten zur PrĂ€vention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
EA200000409A1 (ru) 1997-10-10 2000-10-30 ĐĄĐ°ĐčŃ‚ĐŸĐČоэ, Đ˜ĐœĐș. ĐĄĐŸĐ”ĐŽĐžĐœĐ”ĐœĐžĐ”, Ń„Đ°Ń€ĐŒĐ°Ń†Đ”ĐČтОчДсĐșая ĐșĐŸĐŒĐżĐŸĐ·ĐžŃ†ĐžŃ, ŃĐżĐŸŃĐŸĐ± ĐžĐœĐłĐžĐ±ĐžŃ€ĐŸĐČĐ°ĐœĐžŃ гОбДлО ĐșлДтĐșĐž ĐČ ĐŸĐŽĐœĐŸĐč ĐșлДтĐșĐ” ОлО тĐșĐ°ĐœĐž, ŃĐżĐŸŃĐŸĐ± Đ»Đ”Ń‡Đ”ĐœĐžŃ ОлО ŃĐœĐžĐ¶Đ”ĐœĐžŃ ĐșĐ»Đ”Ń‚ĐŸŃ‡ĐœĐŸĐč ŃĐŒĐ”Ń€Ń‚Đž, ŃĐżĐŸŃĐŸĐ± Đ»Đ”Ń‡Đ”ĐœĐžŃ ОлО ĐżŃ€ĐŸŃ„ĐžĐ»Đ°ĐșтоĐșĐž ĐżĐŸĐ»ĐžĐșĐžŃŃ‚ĐŸĐ·ĐœĐŸĐłĐŸ Đ·Đ°Đ±ĐŸĐ»Đ”ĐČĐ°ĐœĐžŃ ĐżĐŸŃ‡Đ”Đș ОлО Đ°ĐœĐ”ĐŒĐžĐž/ŃŃ€ĐžŃ‚Ń€ĐŸĐżĐŸŃĐ·Đ° у жОĐČĐŸŃ‚ĐœŃ‹Ń…, ŃĐżĐŸŃĐŸĐ± защОты ĐŸŃ€ĐłĐ°ĐœĐ° ОлО тĐșĐ°ĐœĐž ĐŒĐ»Đ”ĐșĐŸĐżĐžŃ‚Đ°ŃŽŃ‰Đ”ĐłĐŸ ĐŸŃ‚ гОбДлО ĐșĐ»Đ”Ń‚ĐŸĐș, ŃĐżĐŸŃĐŸĐ± ŃĐœĐžĐ¶Đ”ĐœĐžŃ ОлО ĐżŃ€ĐŸŃ„ĐžĐ»Đ°ĐșтоĐșĐž гОбДлО ĐșĐ»Đ”Ń‚ĐŸĐș ĐČ ĐŸŃ€ĐłĐ°ĐœĐ” ОлО тĐșĐ°ĐœĐž ĐŽĐŸĐœĐŸŃ€Đ° ĐżĐŸŃĐ»Đ” ох Ń‚Ń€Đ°ĐœŃĐżĐ»Đ°ĐœŃ‚Đ°Ń†ĐžĐž, ŃĐżĐŸŃĐŸĐ± ŃĐœĐžĐ¶Đ”ĐœĐžŃ ОлО ĐżŃ€Đ”ĐŽĐŸŃ‚ĐČŃ€Đ°Ń‰Đ”ĐœĐžŃ гОбДлО ŃĐżĐ”Ń€ĐŒŃ‹ ОлО яĐčцДĐșĐ»Đ”Ń‚ĐŸĐș
US6267952B1 (en) * 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
JP2000026421A (ja) 1998-01-29 2000-01-25 Kumiai Chem Ind Co Ltd ゾケăƒȘâ€•ăƒ«ă‚čăƒ«ăƒ•ă‚Łăƒ‰èȘ˜ć°Žäœ“ćŠăłæœ‰ćźłç”Ÿç‰©é˜Č陀所
WO1999041253A1 (en) 1998-02-17 1999-08-19 Tularik Inc. Anti-viral pyrimidine derivatives
WO1999047154A1 (en) 1998-03-16 1999-09-23 Cytovia, Inc. Dipeptide caspase inhibitors and the use thereof
PL204628B1 (pl) 1998-06-02 2010-01-29 Osi Pharmaceuticals Pochodna pirolo[2,3d]pirymidyny, jej zastosowanie i sposoby wytwarzania tej pochodnej i preparaty farmaceutyczne
JP4533534B2 (ja) * 1998-06-19 2010-09-01 ăƒŽăƒăƒ«ăƒ†ă‚Łă‚č ăƒă‚Żă‚·ăƒłă‚ș ケンド ăƒ€ă‚€ă‚ąă‚°ăƒŽă‚čティックă‚čïŒŒă‚€ăƒłă‚łăƒŒăƒăƒŹăƒŒăƒ†ăƒƒăƒ‰ グăƒȘă‚łăƒŒă‚Čăƒłă‚·ăƒłă‚żăƒŒă‚Œă‚­ăƒŠăƒŒă‚ŒïŒ“ăźă‚€ăƒłăƒ’ăƒ“ă‚żăƒŒ
WO2000003901A1 (de) * 1998-07-16 2000-01-27 Continental Teves Ag & Co. Ohg Verfahren und vorrichtung zum ermitteln von kritischen fahrzustÀnden bei im fahrbetrieb befindlichen fahrzeugen
EP1105394A1 (en) * 1998-08-21 2001-06-13 Du Pont Pharmaceuticals Company ISOXAZOLO 4,5-d]PYRIMIDINES AS CRF ANTAGONISTS
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
ATE294796T1 (de) * 1998-10-08 2005-05-15 Astrazeneca Ab Chinazolin derivate
GB9828640D0 (en) 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6545030B1 (en) 1999-01-13 2003-04-08 Warner-Lambert Company 1-heterocycle substituted diarylamines
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
CA2366857C (en) 1999-03-30 2010-12-14 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
EP1185528A4 (en) 1999-06-17 2003-03-26 Shionogi Biores Corp INHIBITORS OF IL-12 PRODUCTION
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
NZ517694A (en) 1999-08-13 2005-03-24 Vertex Pharma Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
CA2386218A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
EA200200411A1 (ru) 1999-11-30 2002-10-31 ПфаĐčзДр ĐŸŃ€ĐŸĐŽĐ°Đșтс Đ˜ĐœĐș. 2,4-ĐŽĐžĐ°ĐŒĐžĐœĐŸĐżĐžŃ€ĐžĐŒĐžĐŽĐžĐœĐŸĐČŃ‹Đ” ŃĐŸĐ”ĐŽĐžĐœĐ”ĐœĐžŃ, ĐżĐŸĐ»Đ”Đ·ĐœŃ‹Đ” ĐČ ĐșачДстĐČĐ” ĐžĐŒĐŒŃƒĐœĐŸŃŃƒĐżŃ€Đ”ŃŃĐŸŃ€ĐŸĐČ
DK1246623T3 (da) 1999-12-02 2006-11-13 Osi Pharm Inc Forbindelser, som er specifikke for adenosin A1-, A2a- og A3-receptor og anvendelser deraf
MY125768A (en) 1999-12-15 2006-08-30 Bristol Myers Squibb Co N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6376489B1 (en) 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
JP4794793B2 (ja) 1999-12-28 2011-10-19 ăƒ•ă‚ĄăƒŒăƒžă‚łăƒšă‚€ă‚ąïŒŒ ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïŒźâˆ’ăƒ˜ăƒ†ăƒ­ç’°ïŒŽïŒźïŒŠâˆ’Î±ç™șçŸé˜»ćźłć‰€
US20020065270A1 (en) * 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
BR0104424A (pt) * 2000-02-05 2002-01-08 Vertex Pharma ComposiçÔes de pirazol Ășteis como inibidores de erk
US20030004174A9 (en) * 2000-02-17 2003-01-02 Armistead David M. Kinase inhibitors
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
EP1268519B1 (en) 2000-04-03 2005-06-15 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
BR0110302A (pt) 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteĂŹnas cinase, sal e prĂł-droga farmaceuticamente aceitĂĄvel, metabĂłlito farmaceuticamente ativo ou sal farmaceuticamente aceitĂĄvel de metabĂłlito, composição farmacĂȘutica, mĂ©todo de tratamento de condição doentia em mamĂŹferos mediada pela atividade de proteĂŹna cinase, mĂ©todo de modulação ou inibição da atividade de um receptor de proteĂŹna cinase
JP3890184B2 (ja) * 2000-05-15 2007-03-07 ïŒźïœ…ïœƒăƒ‘ăƒŒă‚œăƒŠăƒ«ăƒ—ăƒ­ăƒ€ă‚Żăƒ„æ ȘćŒäŒšç€Ÿ 電æșèŁ…çœźćŠăłăăźé›»ćŠ›ćˆ¶ćŸĄæ–čæł•ă€æƒ…ć ±ć‡Šç†æ©Ÿć™š
EP1299381B1 (en) * 2000-06-28 2008-05-07 AstraZeneca AB Substituted quinazoline derivatives and their use as inhibitors
RU2355700C9 (ru) 2000-07-21 2010-03-20 ĐšĐ”Ń€ĐžĐœĐł ĐšĐŸŃ€ĐżĐŸŃ€Đ”ĐčŃˆĐœ ĐĐŸĐČŃ‹Đ” пДптОЎы ĐșĐ°Đș ĐžĐœĐłĐžĐ±ĐžŃ‚ĐŸŃ€Ń‹ ns3-ŃĐ”Ń€ĐžĐœĐżŃ€ĐŸŃ‚Đ”Đ°Đ·Ń‹ ĐČоруса гДпатОта с
SK2002003A3 (en) 2000-08-31 2004-04-06 Pfizer Prod Inc Pyrazole derivatives and their use as protein kinase inhibitors
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ATE335737T1 (de) * 2000-09-15 2006-09-15 Vertex Pharma Isoxazole und ihre verwendung als erk-inhibitoren
ATE346064T1 (de) 2000-09-15 2006-12-15 Vertex Pharma Pyrazolverbindungen als protein-kinasehemmer
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) * 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CN1474815A (zh) 2000-09-20 2004-02-11 ÄŹïżœïżœŚšïżœïżœïżœÉ·ïżœïżœïżœïżœȚčïżœËŸ 4-æ°šćŸș-ć–č攑敉
US6641579B1 (en) 2000-09-29 2003-11-04 Spectrasonics Imaging, Inc. Apparatus and method for ablating cardiac tissue
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
DE10061863A1 (de) * 2000-12-12 2002-06-13 Basf Ag Verfahren zur Herstellung von Triethylendiamin (TEDA)
AU2002228922A1 (en) 2000-12-12 2002-06-24 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
ATE354573T1 (de) 2000-12-21 2007-03-15 Vertex Pharma ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
EP1373257B9 (en) * 2001-03-29 2008-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
US6642227B2 (en) * 2001-04-13 2003-11-04 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
US20030096813A1 (en) * 2001-04-20 2003-05-22 Jingrong Cao Compositions useful as inhibitors of GSK-3
AU2002308748A1 (en) * 2001-05-16 2002-11-25 Vertex Pharmaceuticals Incorporated Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
CA2450769A1 (en) * 2001-06-15 2002-12-27 Vertex Pharmaceuticals Incorporated 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors
JP4342937B2 (ja) * 2001-07-03 2009-10-14 ăƒăƒŒăƒ†ăƒƒă‚Żă‚č ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïŒłïœ’ïœƒăŠă‚ˆăłïŒŹïœƒïœ‹ă‚żăƒłăƒ‘ă‚ŻèłȘă‚­ăƒŠăƒŒă‚Œăźé˜»ćźłć‰€ăšă—ăŠăźă‚€ă‚œă‚­ă‚”ă‚ŸăƒŒăƒ«ăƒ”ăƒȘミゾン
WO2003026665A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
US6569499B2 (en) 2001-10-02 2003-05-27 Xerox Corporation Apparatus and method for coating photoreceptor substrates
DE60236322D1 (de) * 2001-12-07 2010-06-17 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
EP1485381B8 (en) * 2002-03-15 2010-05-12 Vertex Pharmaceuticals Incorporated Azolylaminoazine as inhibitors of protein kinases
US7091343B2 (en) * 2002-03-15 2006-08-15 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
DE60314603T2 (de) * 2002-03-15 2008-02-28 Vertex Pharmaceuticals Inc., Cambridge Zusammensetzungen brauchbar als protein-kinase-inhibitoren
EP1485380B1 (en) * 2002-03-15 2010-05-19 Vertex Pharmaceuticals Incorporated Azolylaminoazines as inhibitors of protein kinases
US20030207873A1 (en) * 2002-04-10 2003-11-06 Edmund Harrington Inhibitors of Src and other protein kinases
WO2003091246A1 (en) * 2002-04-26 2003-11-06 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
US7361665B2 (en) * 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
CN1319968C (zh) 2002-08-02 2007-06-06 æČƒæł°ć…‹æ–ŻèŻç‰©è‚Ąä»œæœ‰é™ć…Źćž 甚䜜gsk3çš„æŠ‘ćˆ¶ć‰‚çš„ćĄć”‘ç»„ćˆç‰©
WO2007041358A2 (en) 2005-09-30 2007-04-12 Miikana Therapeutics, Inc. Substituted pyrazole compounds
DE602007007985D1 (de) 2006-12-19 2010-09-02 Vertex Pharma Als inhibitoren von proteinkinasen geeignete aminopyrimidine

Also Published As

Publication number Publication date
NZ526474A (en) 2005-10-28
MY140377A (en) 2009-12-31
US20080287444A1 (en) 2008-11-20
HK1061389A1 (en) 2004-09-17
NO20032703D0 (no) 2003-06-13
US6653300B2 (en) 2003-11-25
CN1486312A (zh) 2004-03-31
WO2002050065A2 (en) 2002-06-27
HK1062433A1 (en) 2004-11-05
WO2002057259A3 (en) 2003-04-24
EP2264028A1 (en) 2010-12-22
JP2004518743A (ja) 2004-06-24
DK1353916T3 (da) 2007-01-29
ATE326460T1 (de) 2006-06-15
DK1345922T3 (da) 2006-09-18
PL210414B1 (pl) 2012-01-31
JP4160389B2 (ja) 2008-10-01
ES2265452T3 (es) 2007-02-16
MXPA03005612A (es) 2003-10-06
KR20030061466A (ko) 2003-07-18
NZ526469A (en) 2005-10-28
HUP0400908A3 (en) 2010-03-29
JP2008247921A (ja) 2008-10-16
IL209827A0 (en) 2011-02-28
DE60123283D1 (de) 2006-11-02
DE60123283T2 (de) 2007-04-12
CY1106297T1 (el) 2011-10-12
CA2432132A1 (en) 2002-08-01
MXPA03005611A (es) 2003-10-06
EP1345922A1 (en) 2003-09-24
DE60119777D1 (de) 2006-06-22
AP1588A (en) 2006-03-06
ATE326463T1 (de) 2006-06-15
PL210066B1 (pl) 2011-11-30
NO20032704L (no) 2003-08-21
JP2008201808A (ja) 2008-09-04
ATE528303T1 (de) 2011-10-15
CA2432222A1 (en) 2002-08-15
KR100843114B1 (ko) 2008-07-02
WO2002068415A1 (en) 2002-09-06
US20030055068A1 (en) 2003-03-20
CA2432872C (en) 2008-09-23
ATE326461T1 (de) 2006-06-15
KR100947185B1 (ko) 2010-03-15
WO2002050065A3 (en) 2002-10-24
EP1345922B1 (en) 2006-05-31
US20030004161A1 (en) 2003-01-02
EP1353916A2 (en) 2003-10-22
NZ526473A (en) 2005-06-24
US20030036543A1 (en) 2003-02-20
US8697698B2 (en) 2014-04-15
BR0116411A (pt) 2003-11-11
EP1353916B1 (en) 2006-09-20
US20140187772A1 (en) 2014-07-03
KR20030061464A (ko) 2003-07-18
CN1487933A (zh) 2004-04-07
KR20030061467A (ko) 2003-07-18
NO20032670D0 (no) 2003-06-12
PT1345922E (pt) 2006-09-29
DE60126658D1 (de) 2007-03-29
AU2002231166B2 (en) 2008-02-21
US6989385B2 (en) 2006-01-24
AU2006201267A1 (en) 2006-04-27
DE60119775D1 (de) 2006-06-22
JP2004517894A (ja) 2004-06-17
JP5249842B2 (ja) 2013-07-31
US7087603B2 (en) 2006-08-08
CN1486311A (zh) 2004-03-31
WO2002059112A3 (en) 2003-02-06
JP4234435B2 (ja) 2009-03-04
IL156389A (en) 2011-01-31
IL156407A0 (en) 2004-01-04
PT1355905E (pt) 2007-05-31
HK1060349A1 (en) 2004-08-06
HUP0400639A2 (hu) 2004-06-28
WO2002059112A2 (en) 2002-08-01
KR20030061463A (ko) 2003-07-18
DE60120219T2 (de) 2007-04-12
ES2265450T3 (es) 2007-02-16
US6727251B2 (en) 2004-04-27
MXPA03005610A (es) 2003-10-06
CA2432222C (en) 2008-07-29
ATE326462T1 (de) 2006-06-15
KR20030061468A (ko) 2003-07-18
US20040157893A1 (en) 2004-08-12
NO328501B1 (no) 2010-03-01
AR042169A1 (es) 2005-06-15
US20040214814A1 (en) 2004-10-28
DE60119774D1 (de) 2006-06-22
NO328537B1 (no) 2010-03-15
NZ526470A (en) 2006-03-31
AP2003002816A0 (en) 2003-06-30
ATE340172T1 (de) 2006-10-15
CA2432132C (en) 2008-07-29
TWI313269B (en) 2009-08-11
DE60119777T2 (de) 2007-05-03
JP2009155352A (ja) 2009-07-16
KR20030061858A (ko) 2003-07-22
CN100340555C (zh) 2007-10-03
EP1345928B1 (en) 2007-02-14
US7625913B2 (en) 2009-12-01
MXPA03005608A (es) 2003-10-06
TWI290551B (en) 2007-12-01
HUP0400842A2 (hu) 2004-07-28
AU2001297619B2 (en) 2006-06-08
CN100406454C (zh) 2008-07-30
US7982037B2 (en) 2011-07-19
US8304414B2 (en) 2012-11-06
NO20032703L (no) 2003-08-19
PT1353916E (pt) 2007-01-31
NO20032704D0 (no) 2003-06-13
DE60119774T2 (de) 2007-05-16
CA2432131C (en) 2008-07-08
US20130096128A1 (en) 2013-04-18
DE60126658T2 (de) 2007-11-22
JP2004516291A (ja) 2004-06-03
AP2003002825A0 (en) 2003-09-30
US20050038023A1 (en) 2005-02-17
KR100909665B1 (ko) 2009-07-29
ES2375491T3 (es) 2012-03-01
HK1060346A1 (en) 2004-08-06
US20040132781A1 (en) 2004-07-08
DE60119776T2 (de) 2007-05-16
JP2009286805A (ja) 2009-12-10
CA2432129A1 (en) 2002-07-25
CA2432131A1 (en) 2002-08-01
CA2432303C (en) 2010-04-13
WO2002059111A2 (en) 2002-08-01
JP2008189687A (ja) 2008-08-21
TW200716617A (en) 2007-05-01
US6664247B2 (en) 2003-12-16
NO20032671D0 (no) 2003-06-12
US20030004164A1 (en) 2003-01-02
IL156408A0 (en) 2004-01-04
ES2272567T3 (es) 2007-05-01
CA2432303A1 (en) 2002-08-29
US20030105090A1 (en) 2003-06-05
KR20030061465A (ko) 2003-07-18
AU2002246754B2 (en) 2006-06-08
NZ526471A (en) 2005-08-26
ES2280313T3 (es) 2007-09-16
NO330527B1 (no) 2011-05-09
HUP0400639A3 (en) 2010-03-29
MXPA03005609A (es) 2003-10-06
US20040167141A1 (en) 2004-08-26
EP1702920B1 (en) 2011-10-12
JP2004517927A (ja) 2004-06-17
KR20030061857A (ko) 2003-07-22
EP1345926B1 (en) 2006-05-17
NO20032670L (no) 2003-08-15
MXPA03005606A (es) 2003-10-06
DE60119776D1 (de) 2006-06-22
EP1345929B1 (en) 2006-05-17
ATE327989T1 (de) 2006-06-15
IL156368A0 (en) 2004-01-04
HK1059776A1 (en) 2004-07-16
DE60120219D1 (de) 2006-07-06
SI1355905T1 (sl) 2007-08-31
JP4160392B2 (ja) 2008-10-01
HUP0400908A2 (hu) 2004-07-28
DE60126828D1 (de) 2007-04-05
CA2432799C (en) 2008-08-19
CA2432223C (en) 2008-05-20
IL156389A0 (en) 2004-01-04
HK1060347A1 (en) 2004-08-06
ATE353890T1 (de) 2007-03-15
JP2004516292A (ja) 2004-06-03
CN1486310A (zh) 2004-03-31
EP1345929A2 (en) 2003-09-24
CA2432872A1 (en) 2002-06-27
ATE354573T1 (de) 2007-03-15
AR042397A1 (es) 2005-06-22
WO2002062789A1 (en) 2002-08-15
PL363244A1 (en) 2004-11-15
NZ526468A (en) 2004-03-26
CA2432799A1 (en) 2002-06-27
DK1355905T3 (da) 2007-06-18
US20090312543A1 (en) 2009-12-17
EP1345927A1 (en) 2003-09-24
EP1345928A2 (en) 2003-09-24
JP2004518703A (ja) 2004-06-24
WO2002057259A2 (en) 2002-07-25
CA2432223A1 (en) 2002-09-06
EP1345925A2 (en) 2003-09-24
MXPA03005605A (es) 2003-10-06
AU2006201267B2 (en) 2010-07-29
ES2265446T3 (es) 2007-02-16
NZ526472A (en) 2004-04-30
CN102250071A (zh) 2011-11-23
IL156369A0 (en) 2004-01-04
EP1345927B1 (en) 2006-05-17
JP2004517926A (ja) 2004-06-17
JP4160395B2 (ja) 2008-10-01
US6653301B2 (en) 2003-11-25
JP2013213068A (ja) 2013-10-17
JP2008260767A (ja) 2008-10-30
US7427681B2 (en) 2008-09-23
JP2008189682A (ja) 2008-08-21
EP1355905B1 (en) 2007-02-21
MXPA03005607A (es) 2003-10-06
WO2002066461A1 (en) 2002-08-29
CN100408573C (zh) 2008-08-06
HUP0400641A3 (en) 2010-03-29
CN1549812A (zh) 2004-11-24
HUP0400638A2 (hu) 2004-06-28
HK1062565A1 (zh) 2004-11-12
DE60126828T2 (de) 2007-11-08
EP1355905A1 (en) 2003-10-29
JP2005097322A (ja) 2005-04-14
CN100436452C (zh) 2008-11-26
PL363246A1 (en) 2004-11-15
CA2432129C (en) 2008-08-26
WO2002059111A3 (en) 2003-01-09
AU2002255452B2 (en) 2006-06-08
JP2008247920A (ja) 2008-10-16
RU2355688C2 (ru) 2009-05-20
DE60119775T2 (de) 2007-05-10
NO20032736D0 (no) 2003-06-16
WO2002050066A2 (en) 2002-06-27
EP1702920A1 (en) 2006-09-20
AR042398A1 (es) 2005-06-22
AU3116602A (en) 2002-07-01
NO20032671L (no) 2003-08-18
KR100875091B1 (ko) 2008-12-22
US7531536B2 (en) 2009-05-12
AU2002234047A1 (en) 2002-07-01
JP2008222719A (ja) 2008-09-25
ES2266095T3 (es) 2007-03-01
EP1345926A2 (en) 2003-09-24
JP2004519479A (ja) 2004-07-02
WO2002050066A3 (en) 2003-01-23
KR100889246B1 (ko) 2009-03-19
HK1060557A1 (en) 2004-08-13
IL156369A (en) 2011-02-28
US6656939B2 (en) 2003-12-02
EP1345925B1 (en) 2006-05-17
HUP0400641A2 (hu) 2004-06-28
JP4210520B2 (ja) 2009-01-21
US20030022885A1 (en) 2003-01-30
US20030078275A1 (en) 2003-04-24
NO20032736L (no) 2003-08-18
SI1353916T1 (sl) 2007-02-28
BR0116493A (pt) 2003-09-30
NZ526475A (en) 2005-06-24
RU2003122209A (ru) 2005-02-10

Similar Documents

Publication Publication Date Title
AR040925A1 (es) Compuestos de pirazol utiles como inhibidores de proteinquinasa
AR126701A1 (es) Derivados de n-ciclopropilpirido[4,3-d]pirimidin-4-amina y usos de los mismos
DOP2022000039A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
CA2422378A1 (en) Pyrazole compounds useful as protein kinase inhibitors
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR041184A1 (es) Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso
UY26143A1 (es) Derivados heterocĂ­clicos Ăștiles como agentes anticancerosos
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
GT200000161A (es) Compuestos para el tratamiento de la isquemia.
AR056763A1 (es) Aminopirimidinas sustituidas con tiazol o pirazol,utiles como agentes anticancer y composiciones farmaceuticas que las contienen.
AR037329A1 (es) Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos
AR034858A1 (es) Compuestos elevadores de abca-1,composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento
AR044909A1 (es) Derivados de tiazolilpiperidina, procesos para su preparacion, composiciones farmaceuticas que los comprenden y aplicaciones de dichos derivados en el tratamiento de hipertrigliceridemia , hipercolesterolemia y dislipidemia
AR020032A1 (es) Derivados de 1,3 -metil eritromicina.
AR045155A1 (es) Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
MX9306311A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR045156A1 (es) Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
ES2068742B1 (es) Nuevos derivados de piridinio.
MX2024012470A (es) Inhibidores de cinasas dependientes de ciclina 9 (cdk9)
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
DE60214401D1 (de) Hetero-bicyclische crf antagonisten
DOP2001000296A (es) Derivados de la piperazina disustituida 1,4-utiles como bloqueadores de adrenoceptores uro-selectivos 1
AR116036A1 (es) DERIVADOS DE NAFTIRIDINA COMO INHIBIDORES DE INTEGRINA avb6
AR125963A1 (es) Inhibidores de alk2 quinasa que contienen imidazol
AR035852A1 (es) Un compuesto de (pirimidin-substituido-4-il)-(pirazol-substituido-3-il)-amino, composiciones farmaceuticas que lo comprenden, uso de dicha composicion farmaceutica para la preparacion de medicamentos y compuestos intermedios para la sintesis de dicho compuesto

Legal Events

Date Code Title Description
FG Grant, registration